NEW YORK, April 24, 2019 /PRNewswire/ -- Moore Kuehn,
PLLC, a securities law firm located on Wall Street in downtown
New York City, is investigating
whether certain officers and directors of Esperion
Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary
duties to shareholders.
According to a federal securities lawsuit, Esperion made
materially false and misleading statements regarding the Company's
business, operational and compliance policies. Esperion made false
and/or misleading statements and/or failed to disclose that: (i)
Esperion's cholesterol-lowering medication, bempedoic acid,
entailed serious undisclosed safety risks, including death; and
(ii) as a result of the foregoing, Esperion's public statements
were materially false and misleading at all relevant times.
Esperion Therapeutics, Inc. is a public American
pharmaceutical company focused on the development of bempedoic
acid.
Moore Kuehn encourages shareholders to contact Fletcher Moore, Esq. by email at
fmoore@moorekuehn.com or telephone at (212) 709-8245. There
is no cost or obligation to you.
Moore Kuehn is a New York-based
law firm with attorneys representing investors and consumers in
litigation involving securities law violations, financial fraud,
breaches of fiduciary duties, and other claims. For
additional information about Moore Kuehn, please go to
www.moorekuehn.com. ATTORNEY ADVERTISING. Prior results do
not guarantee similar outcomes.
Contacts:
Moore Kuehn, PLLC
Fletcher Moore, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
fmoore@moorekuehn.com
(212) 709-8245
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-esperion-therapeutics-inc-investors-to-contact-law-firm-for-possible-claims-against-officers-and-directors-300837657.html
SOURCE Moore Kuehn, PLLC